GlassScriptPhysician profile
Leslie Yonemoto
NPI 1336235456
$2,765.53
in general payments reported to CMS, 2019-2025
30 companies · $556 in 2025
The $556 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.62 · 2020: $113 · 2021: $44.53 · 2022: $303 · 2023: $911 · 2024: $767 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Entertainment: $37.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.87 |
| Entertainment | $37.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $1,398.63 | 2022-2025 | Elekta Medical Linear Accelerator, Elekta Unity |
| Accuray Incorporated | $214.36 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $127.38 | 2022-2025 | |
| Genmab U.S., INC. | $124.55 | 2022 | |
| Stemline Therapeutics INC. | $121.81 | 2023 | Orserdu |
| Ge Healthcare | $82.86 | 2025 | |
| Daiichi Sankyo INC. | $73.62 | 2022-2024 | Enhertu |
| Genzyme Corporation | $72.67 | 2022-2023 | |
| Eisai INC. | $48.97 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $34.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $31.32 | 2020-2023 | Imfinzi |
| Sobi, INC | $31.16 | 2023 | |
| Celgene Corporation | $29.77 | 2021 | |
| Icotec Medical INC. | $28.22 | 2024 | Icotec Blackarmor Spine System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $27.86 | 2025 | Rybrevant |
| Puma Biotechnology, INC. | $27.11 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.33 | 2023 | Ninlaro |
| Novocure INC. | $25.28 | 2019 | |
| Tersera Therapeutics LLC | $24.57 | 2023 | Zoladex |
| Fortovia Therapeutics, INC. | $23.68 | 2019 | |
| Incyte Corporation | $21.47 | 2025 | Monjuvi |
| Geron Corporation | $20.44 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $19.54 | 2025 | Libtayo |
| Agios Pharmaceuticals, INC. | $19.38 | 2024 | Pyrukynd |
| Kyowa Kirin, INC. | $18.31 | 2023 | Poteligeo |
| Azurity Pharmaceuticals, INC. | $15.83 | 2025 | Danziten |
| Lilly USA, LLC | $15.60 | 2023 | Jaypirca, Verzenio |
| Seagen INC. | $14.76 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.26 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Yonemoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.